4. A small Canadian firm that has developed valuable new medical products using its unique biotechnology knowhow is trying to decide how best to serve the European Union market. Its choices are given on the next page.

The cost of investment in manufacturing facilities will be a major one for the Canadian firm, but it is not outside its reach. If these are the firm’s only options, which one would you advise it to choose? Why?